healthcareandpharma (3) - PowerPoint PPT Presentation

About This Presentation
Title:

healthcareandpharma (3)

Description:

Mifeprex 200 Mg (mifepristone) is a medication that inhibits the production of a hormone called progesterone, which is required for a pregnancy to proceed. – PowerPoint PPT presentation

Number of Views:23
Slides: 7
Provided by: healthcareandpharma
Category: Other

less

Transcript and Presenter's Notes

Title: healthcareandpharma (3)


1
Questions and answers on the FDA approved drug
Mifeprex
  • https//www.safeabortionpharma.com

2
Mifeprex What is it and how does it work?
  • Mifeprex 200 Mg (mifepristone) is a medication
    that inhibits the production of a hormone called
    progesterone, which is required for a pregnancy
    to proceed. Mifeprex is used to terminate an
    early pregnancy when combined with another
    medication called misoprostol (12 weeks or less
    since the first day of the last menstrual
    period).

3
What revisions did FDA approve last on the
Mifeprex application?
  • Mifeprex pills online were approved by the FDA
    for the first time in 2000. The FDA approved a
    supplementary application submitted by the
    biopharmaceutical company that markets Mifeprex
    in 2016. This approval included changes to the
    Mifeprex dose and the Mifeprex and misoprostol
    dosing regimen (including the misoprostol dose
    and a change in the route of misoprostol
    administration from oral to buccal (in the cheek
    pouch), the interval between taking Mifeprex and
    misoprostol, and the location at which the woman
    may take misoprostol.

4
  • The approval also changed the gestational age at
    which Mifeprex has been proved to be safe and
    effective. Furthermore, the labeling was changed
    to satisfy the FDA's current labeling criteria.
    The FDA also approved revisions to the current
    Risk Evaluation and Mitigation Strategy (REMS) to
    reflect the changes allowed in the additional
    application and to align the Mifeprex REMS with
    more recently approved REMS.

5
  • Notably, the FDA granted a supplemental
    application for Mifeprex on April 11, 2019,
    authorizing modifications to the existing
    approved REMS for Mifeprex in order to establish
    a single, shared system REMS for mifepristone
    products (including Mifeprex and the approved
    generic version of Mifeprex) for the medical
    termination of intrauterine pregnancy through 84
    days gestation.

6
Thank you
Write a Comment
User Comments (0)
About PowerShow.com